Welwyn Garden City — Cresset is delighted to announce the appointment of Dr Rob Scoffin as Chief Executive Officer of Cresset Group. Rob joins Cresset from CambridgeSoft where, as Vice President of European Operations, he was responsible for significant growth in CambridgeSoft’s European business. Rob replaces Beatrice Leigh, who will now become non-executive Chairman of the Board.

“The appointment of Rob marks an exciting new chapter for Cresset,” said Andy Vinter, Founder and Chief Scientific Officer of Cresset. “Rob has a long track record of close collaboration with customers and successful commercial growth in the computational chemistry market place.” Outgoing CEO and Chairman of the Board, Bea Leigh commented, “We are excited to be working with Rob to further accelerate the company’s development and to achieve our aggressive corporate objectives”.

“This is a fantastic opportunity to join an established company with an excellent scientific reputation, and to help drive growth and enhanced commercial success in the future,” said Rob. “The Cresset team has worked hard to create a world-leading portfolio of products, and I am looking forward to helping bring those to new markets.”

Rob has a D.Phil. in chemistry from Oxford and has recently been instrumental in the development of Electronic Lab Notebook systems which he has deployed at several major pharmaceutical companies. Prior to CambridgeSoft, Rob was CEO (Software) for Amedis and Senior Product Manager at Oxford Molecular.

For further information, please visit www.cresset-group.com

About Cresset Group Ltd

Cresset develops software for calculating and comparing the molecular Field characteristics of chemical compounds. Field technology uses the surface properties of molecules to evaluate their activities and properties, rather than relying on 2D structure similarity, which enables Cresset’s users to find more interesting, novel and relevant results than other methods. Cresset’s Fields provide a smarter, structure independent way of hit-finding, lead switching and lead optimization in drug discovery and other chemistry-based research projects. Cresset’s Field technologies have been successfully applied to a very wide range of target classes, with and without structural information, on over 80 projects for major pharmaceutical and biotechnology companies. www.cresset-group.com